UMB Data Catalog

A project of the Health Sciences and Human Services Library
Find Datasets from
UMB Researchers
Include your dataset
of 1 Next >
Results Found: 3

  • Strain-specific alterations in gut microbiome and host immune responses elicited by tolerogenic Bifidobacterium pseudolongum
    UMB Dataset

    Authors
    Bing Ma
    Samuel J. Gavzy
    Vikas Saxena
    Yang Song
    12 more author(s)...
    Description

    To determine strain-specific driving mechanisms of B. pseudolongum UMB-MBP-01, researchers compared it to porcine tropic strain B. pseudolongum ATCC25526 using cell culture and in vivo experimentation and comparative genomic approaches. The data demonstrates that these two strains possess distinct genetic repertoires in carbohydrate assimilation, differential activation signatures and cytokine responses signatures in innate immune cells, and differential effects on lymph node morphology with unique local and systemic leukocyte distribution.

    Subject
    Immunity
    Access Rights
    Unrestricted access

  • Kinetics of SARS-CoV-2 antibody responses preCOVID-19 and post-COVID-19 convalescent plasma transfusion in patients with severe respiratory failure: an observational case–control study
    UMB Dataset

    Authors
    Magali J. Fontaine
    Matthew N. Klein
    Elizabeth Wenqian Wang
    Paul Zimand
    8 more author(s)...
    Description

    This observational retrospective control study investigated the development of the humoral immune response to SARS-CoV-2 in convalescent plasma (CCP) recipients (n=34) and compared it to the humoral response in a group of patients not treated with CCP (n=68). Additionally, a separate comparison of clinical outcomes was performed between CCP recipients and a matched control group of untreated patients (n=34). Patients considered for enrollment in the study presented with severe COVID-19 and were hospitalized in the intensive care units (ICU) of 3 Maryland hospitals. Participants received a single unit of ABO compatible CCP of approximately 250mL. Blood samples for SARS-CoV-2 antibody titre measurements were collected immediately pre-transfusion (day 0) and on days 3, 7 and 14 post-transfusion. Non-transfused patients were used for comparison of antibody titres. Sample draws from this cohort ranged from 0 to 48 days after the onset of symptoms, which varied in severity. Non-transfused patients used for the clinical outcome analysis were matched to CCP recipients based on sex, age, and on three levels of respiratory support requirement (non-ventilated, mechanically ventilated and ventilated with extracorporeal membrane oxygenation (ECMO)) and were admitted in the same hospital. This dataset includes clinical variables from all transfused and non-transfused participants including: symptoms at presentation, level of respiratory support (mechanical ventilation/ECMO status), comorbidities, other SARS-CoV-2 directed therapies, 30-days in-hospital mortality, number of days on mechanical ventilation, number of days on ECMO support, ICU length of stay (LOS) and hospital LOS. Clinical improvement was assessed primarily on survival at 30 days. Secondary outcomes included the number of days on ventilatory and/or ECMO respiratory support, LOS in the hospital and LOS in the ICU.

    Subject
    COVID-19
    Immunization, Passive
    Geographic Coverage
    Maryland
    Timeframe
    2020
    Access Rights
    Approval required

  • COVID-19 hospitalizations and deaths averted under an accelerated vaccination program in northeastern and southern regions of the USA
    UMB Dataset

    Alternate Title(s)
    COVID-19 Agent Based Model
    Authors
    Thomas N. Vilches
    Pratha Sah
    Seyed M. Moghadas
    Affan Shoukat
    4 more author(s)...
    Description

    An age-stratified agent-based model of COVID-19 was used to simulate outbreaks in states within two U. S. regions. The northeastern region consisted of Connecticut, Massachusetts, Maine, New Hampshire, New Jersey, New York, Pennsylvania, Rhode Island and Vermont. The southern region consisted of Alabama, Arkansas, Delaware, District of Columbia, Florida, Georgia, Kentucky, Louisiana, Maryland, Mississippi, North Carolina, Oklahoma, South Carolina, Tennessee, Texas, Virginia and West Virginia. The model was calibrated using reported incidence of COVID-19 in each state from October 1, 2020 to August 31, 2021. It then projected the number of infections, hospitalizations, and deaths that would be averted between September 2021 and the end of March 2022, if states increased their daily vaccination rate.

    Subject
    COVID-19
    Hospitalization
    Immunization Programs
    Geographic Coverage
    United States
    Access Rights
    Unrestricted access
    Local Experts
    Meagan C. Fitzpatrick

Filter by

Subject Domain
Geographic Coverage
Access Restrictions
Timeframe